Scientific publications
Proteomic Analysis of Low-Grade, Early-Stage Endometrial Carcinoma Reveals New Dysregulated Pathways Associated with Cell Death and Cell Signaling. Scientific Publication
Álvaro López-Janeiro 1 , Ignacio Ruz-Caracuel 1 , Jorge L Ramón-Patino 2 , Vivian De Los Ríos 3 , María Villalba Esparza 4 5 , Alberto Berjón 1 6 , Laura Yébenes 1 6 , Alicia Hernández 7 8 , Ivan Masetto 9 , Ece Kadioglu 10 , Virginie Goubert 9 , Victoria Heredia-Soto 5 11 , Rodrigo Barderas 12 , José Ignacio Casal 13 , Carlos E de Andrea 4 , Andrés Redondo 2 8 11 , Marta Mendiola 5 6 , Alberto Peláez-García 6 , David Hardisson 1 5 6 8
Abstract
Low-grade, early-stage endometrial carcinoma (EC) is the most frequent malignant tumor of the uterine corpus. However, the molecular alterations that underlie these tumors are far from being fully understood.
The purpose of this study is to describe dysregulated molecular pathways from EC patients. Sixteen samples of tumor tissue and paired healthy controls were collected and both were subjected to mass spectrometry (MS)/MS proteomic analysis.
Gene ontology and pathway analysis was performed to discover dysregulated pathways and/or proteins using different databases and bioinformatic tools. Dysregulated pathways were cross-validated in an independent external cohort. Cell signaling, immune response, and cell death-associated pathways were robustly identified.
The SLIT/ROBO signaling pathway demonstrated dysregulation at the proteomic and transcriptomic level. Necroptosis and ferroptosis were cell death-associated processes aberrantly regulated, in addition to apoptosis. Immune response-associated pathways showed a dominance of innate immune responses. Tumor immune infiltrates measured by immunofluorescence demonstrated diverse lymphoid and myeloid populations.
Our results suggest a role of SLIT/ROBO, necroptosis, and ferroptosis, as well as a prominent role of innate immune response in low-grade, early-stage EC. These results could guide future research in this group of tumors.
CITATION Cancers (Basel). 2021 Feb 14;13(4):794. doi: 10.3390/cancers13040794
Our authors
